Y Intercept Hong Kong Ltd Sells 3,454 Shares of Charles River Laboratories International, Inc. $CRL

Y Intercept Hong Kong Ltd lowered its position in shares of Charles River Laboratories International, Inc. (NYSE:CRL) by 36.9% in the first quarter, according to its most recent disclosure with the SEC. The institutional investor owned 5,914 shares of the medical research company’s stock after selling 3,454 shares during the quarter. Y Intercept Hong Kong Ltd’s holdings in Charles River Laboratories International were worth $1,020,000 as of its most recent SEC filing.

A number of other institutional investors also recently modified their holdings of the business. Tema Etfs LLC bought a new position in Charles River Laboratories International during the fourth quarter worth about $26,000. Los Angeles Capital Management LLC acquired a new position in shares of Charles River Laboratories International during the 4th quarter worth approximately $42,000. Sfam LLC bought a new position in shares of Charles River Laboratories International during the fourth quarter worth approximately $43,000. Activest Wealth Management increased its holdings in shares of Charles River Laboratories International by 10,900.0% during the fourth quarter. Activest Wealth Management now owns 220 shares of the medical research company’s stock worth $44,000 after purchasing an additional 218 shares during the period. Finally, Geneos Wealth Management Inc. raised its position in shares of Charles River Laboratories International by 98.0% in the second quarter. Geneos Wealth Management Inc. now owns 293 shares of the medical research company’s stock valued at $44,000 after buying an additional 145 shares in the last quarter. Institutional investors own 98.91% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently issued reports on CRL shares. Weiss Ratings raised Charles River Laboratories International from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Wednesday, July 1st. JPMorgan Chase & Co. reduced their target price on Charles River Laboratories International from $165.00 to $160.00 and set a “neutral” rating on the stock in a report on Monday, April 13th. Robert W. Baird set a $213.00 price target on Charles River Laboratories International in a research report on Friday, May 8th. BNP Paribas Exane set a $250.00 price target on Charles River Laboratories International in a research note on Wednesday, July 1st. Finally, Royal Bank Of Canada assumed coverage on shares of Charles River Laboratories International in a research note on Tuesday, April 14th. They set an “outperform” rating and a $215.00 price objective on the stock. Twelve equities research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Charles River Laboratories International has a consensus rating of “Moderate Buy” and a consensus target price of $218.38.

Charles River Laboratories International Price Performance

Shares of CRL traded up $0.19 during mid-day trading on Friday, reaching $233.79. The company had a trading volume of 873,205 shares, compared to its average volume of 808,932. The company has a market capitalization of $11.26 billion, a price-to-earnings ratio of -62.18, a P/E/G ratio of 2.66 and a beta of 1.40. The company has a debt-to-equity ratio of 0.90, a quick ratio of 1.03 and a current ratio of 1.36. The company’s 50 day simple moving average is $187.76 and its 200 day simple moving average is $185.87. Charles River Laboratories International, Inc. has a 1-year low of $144.26 and a 1-year high of $237.86.

Charles River Laboratories International (NYSE:CRL) last issued its quarterly earnings data on Thursday, May 7th. The medical research company reported $2.06 EPS for the quarter, beating the consensus estimate of $1.96 by $0.10. The business had revenue of $995.83 million during the quarter, compared to the consensus estimate of $977.46 million. Charles River Laboratories International had a negative net margin of 4.59% and a positive return on equity of 15.36%. The firm’s revenue was up 1.2% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $2.34 EPS. Charles River Laboratories International has set its FY 2026 guidance at 10.800-11.300 EPS. Analysts expect that Charles River Laboratories International, Inc. will post 11.05 EPS for the current year.

Insider Activity at Charles River Laboratories International

In related news, Director James C. Foster sold 75,000 shares of the firm’s stock in a transaction on Monday, June 29th. The stock was sold at an average price of $225.00, for a total transaction of $16,875,000.00. Following the sale, the director owned 31,596 shares of the company’s stock, valued at $7,109,100. This trade represents a 70.36% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 1.30% of the company’s stock.

Charles River Laboratories International Profile

Charles River Laboratories International, Inc is a leading provider of research models and preclinical and clinical support services for the pharmaceutical, biotechnology and medical device industries. The company’s core offerings include discovery, safety assessment, toxicology, and pathology services, as well as supply of laboratory animals and related diagnostics. Services extend across in vivo and in vitro testing, biologics testing, and support for advanced therapies, helping clients accelerate drug development from early discovery through regulatory submission.

Founded in 1947 in Wilmington, Massachusetts, Charles River has grown through strategic investments and acquisitions to establish a broad portfolio of capabilities.